Ki-67 is an independent indicator in non–muscle invasive bladder cancer (NMIBC); Combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC

Evaluation of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle invasive bladder cancers

“…In a study of 226 patients with bladder-confined cystectomy, Margulis et al found a significant correlation between recurrence and Ki-67 staining, consistent with our results [14]. In 332 patients with bladder cancer, Ding et al found that Ki-67 expression was an independent predictor of both recurrence and progression [15].…”

“…Many studies have shown that Ki-67 and p16 staining are independent immunohistochemical markers predictive of recurrence and progression in bladder cancer [15,19,20,26,27]. As with many tissue section studies, there are various approaches to immunohistochemical evaluation of p16 in the bladder.…”

“…Ki-67 is a nuclear antigen expressed in the G1, S, and G2, but not the G0, phases of the cell cycle. Tumor recurrence and progression are significantly associated with the Ki-67 index in non-muscle invasive bladder cancers [14][15][16].…”

Prognostic role of Ki-67 expression in determination of risk of non-muscle invasive bladder cancer recurrence

“…В иссле-довании, включающем 332 пациента с мышечно-не-инвазивным раком мочевого пузыря, W. Ding и соавт. выявили гиперэкспрессию Ki-67 и тесную связь онко-маркера с более агрессивными проявлениями онко-логического процесса: мультифокальный рост, сопут-ствующая карцинома in situ, более высокая стадия заболевания и низкая дифференцировка опухоли, а также больший риск прогрессирования по таблицам EORTC [24]. Кроме этого, мультивариантный анализ продемонстрировал тесную связь Ki-67 с риском про-грессирования и развития рецидива опухоли, а также с выживаемостью, свободной от рецидива и прогрес-сирования.…”

Malignant lymphoma occurring simultaneously in the urinary bladder wall and bilateral renal parenchyma: A case report

“…Tumor cells are strongly positive for CD79a, CD20 and the bcl2 protein. The proliferative fraction of cells, as determined by Ki-67 staining, is ~70%, compared with <25% of normal urothelial cells of the bladder (3). Frequently, DLBCL tumors are negative for cytokeratins and vimentin.…”